FluTrackers

Tracking Infectious Diseases since 2006

PayPal Verified medpedia.com

FluTrackers.com Inc. is a 501(c)(3) charity

Nederlandse taal Foro de Español de FluTrackers Francophones des FluTrackers Forum Italiano FluTrackers Latest Posts

www www.flutrackers.com



Go Back   FluTrackers > United States > H5N1 Tracking

Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old April 16th, 2006, 12:58 AM
LMonty's Avatar
LMonty LMonty is offline
Advisory Board, Administrator
 
Join Date: Mar 2006
Posts: 867
Default Re: US readies flu pandemic response plan: report

that is downright concerning, and even scary in parts. man, some things just make it all too real, and this article is one of them.
Reply With Quote
  #2  
Old April 16th, 2006, 03:07 PM
KC's Avatar
KC KC is offline
Moderator
 
Join Date: Mar 2006
Location: Southern California
Posts: 408
Default Re: US readies flu pandemic response plan: report

Has anyone seen a copy of the 240 page draft plan that is mentioned in the news article? If so, could you provide a link?

Thanks
Reply With Quote
  #3  
Old April 16th, 2006, 04:40 PM
Bruce Bruce is offline
Registered User
 
Join Date: Feb 2006
Posts: 317
Breaking Bush: drive-through medical

Bush preparing to approve bird flu plan that calls for drive-through medical exams, other steps
LAST UPDATE: 4/16/2006 4:58:26 PM WASHINGTON (AP) - In the event of a bird flu outbreak, U.S. money could be produced overseas and Americans checked in drive-through medical exams for signs of infection, according to government plans being finalized.

Federal officials say the first case of bird flu could show up in the United States in the coming weeks or months as birds migrate from overseas. President Bush is expected to approve a national response plan in the next week or two laying out how agencies should respond if it were transmitted to humans.

The plan assumes a worst-case scenario that as many as 90 million people in the U.S. would become sick and 2 million would die during a worldwide flu pandemic.

It envisions people may need to avoid human contact and stay home from work, school and other large gathering places, according to officials familiar with draft. Some details of the draft, first in Sunday's Washington Post, were confirmed by officials at the White House who spoke anonymously because the plan has not been finalized.

Dr. Bruce Gellin, director of the National Vaccine Program Office at the Health and Human Services Department, said the report builds on the strategy that Bush outlined six months ago - new flu-vaccine technology and greater stockpiles of vaccines and antivirals.

The government had focused on health issues in that earlier report, but a pandemic would affect every aspect of government, Gellin said.

The response plan, assembled by the president's Homeland Security Council, lays out who should be the first vaccinated, proposes that other countries make U.S. money if domestic locations cannot operate. The plan anticipates that employees could strain Internet capacity while working from home computers.

The Veterans Affairs Department has developed a medical exam that could be conducted in VA hospital parking lots, with those who suspect they may be infected able to get a quick exam. The program is modeled after a drive-through flu vaccination program conducted last year.

Dr. Anthony Fauci, the National Institutes of Health's infectious disease chief, said in an interview with The Associated Press last week that scientists are debating whether to vaccinate first those most likely to spread the virus, rather than those traditionally first in line for winter flu shots, including the very old, very young and chronically ill. That policy still is under debate, he said.

---

Associated Press writer Kevin Freking contributed to this report.

-

On the Net:

Government Web site on pandemic flu: http://www.pandemicflu.gov




http://www.wkrc.com/news/national/st...B-D4B5736F5E50
Reply With Quote
  #4  
Old April 16th, 2006, 05:09 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Re: US readies flu pandemic response plan: report

An abstract is here. We may pay for a subscription. Check back tomorrow.

http://www.pnas.org/
__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #5  
Old April 16th, 2006, 05:14 PM
KC's Avatar
KC KC is offline
Moderator
 
Join Date: Mar 2006
Location: Southern California
Posts: 408
Default Re: US readies flu pandemic response plan: report

Thanks Florida1.... The PNAS info will help in reviewing the government plan once it is signed by the President.
__________________
"Predictable is Preventable" by Safety Expert Dr. Gordon Graham.
Reply With Quote
  #6  
Old April 16th, 2006, 06:06 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Re: US readies flu pandemic response plan: report

From the Cover
BIOLOGICAL SCIENCES / MEDICAL SCIENCES

Mitigation strategies for pandemic influenza in the United States
Timothy C. Germann*,, Kai Kadau*, Ira M. Longini, Jr., and Catherine A. Macken*
*Los Alamos National Laboratory, Los Alamos, NM 87545; and Program of Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center and Department of Biostatistics, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98109
Communicated by G. Balakrish Nair, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh, February 16, 2006 (received for review January 10, 2006)


Abstract
Top
Abstract
Results and Discussion
Conclusions
Materials and Methods
Acknowledgements
References

Recent human deaths due to infection by highly pathogenic (H5N1) avian influenza A virus have raised the specter of a devastating pandemic like that of 1917–1918, should this avian virus evolve to become readily transmissible among humans. We introduce and use a large-scale stochastic simulation model to investigate the spread of a pandemic strain of influenza virus through the U.S. population of 281 million individuals for R0 (the basic reproductive number) from 1.6 to 2.4. We model the impact that a variety of levels and combinations of influenza antiviral agents, vaccines, and modified social mobility (including school closure and travel restrictions) have on the timing and magnitude of this spread. Our simulations demonstrate that, in a highly mobile population, restricting travel after an outbreak is detected is likely to delay slightly the time course of the outbreak without impacting the eventual number ill. For R0 < 1.9, our model suggests that the rapid production and distribution of vaccines, even if poorly matched to circulating strains, could significantly slow disease spread and limit the number ill to <10% of the population, particularly if children are preferentially vaccinated. Alternatively, the aggressive deployment of several million courses of influenza antiviral agents in a targeted prophylaxis strategy may contain a nascent outbreak with low R0, provided adequate contact tracing and distribution capacities exist. For higher R0, we predict that multiple strategies in combination (involving both social and medical interventions) will be required to achieve similar limits on illness rates.

antiviral agents | infectious diseases | simulation modeling | social network dynamics | vaccines

It is inevitable that another influenza pandemic will occur, and recent events suggest that this might happen sooner rather than later (1). A highly pathogenic H5N1 influenza A virus appears to have become endemic in avian hosts in Asia, and it is now spreading in migratory birds westward across eastern Europe. Human infections caused by this virus have a high case fatality rate; together with recent genetic data that implicate direct transmission of avian-adapted influenza virus to humans as the cause of the 1918 influenza pandemic (2), these conditions raise the specter of another devastating pandemic. To date, H5N1 viruses cannot transmit readily from human to human, thus providing a window to plan for the pandemic that will occur should the virus evolve to be readily transmissible among humans. If the nascent pandemic is not contained by timely intervention at its source (3, 4), international travel could carry pandemic viruses around the globe within weeks to months of the initiation of the outbreak, causing a worldwide public health emergency.
Intensive pandemic planning is occurring at the national [U.S. Department of Health and Human Services (HHS) Pandemic Influenza Plan, www.hhs.gov/pandemicflu/plan) and international [World Health Organization (WHO) Global Influenza Preparedness Plan, www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5/en/index.html" levels. The most pressing public health questions are: what might be the time course and geographic spread of the outbreak, and what is the most effective utilization of available therapeutic and social resources to minimize the impact of the outbreak? Precise planning is hampered by several unknowns, most critically the eventual human-to-human transmissibility of the human-adapted avian strain (characterized by the basic reproductive numberR0, the average number of secondary infections caused by a single typical infected individual among a completely susceptible population), and the supply of therapeutic agents. Manufacturers of neuraminidase inhibitors, such as oseltamivir, have committed to considerable increases in production over the next 3–4 years. However, the production of vaccine, the traditional first line of defense against influenza virus infections, is hampered by the inability to predict the antigenic details of the evolved virus at the time that it becomes a pandemic strain and the consequent inability to prepare a highly effective vaccine in advance of a pandemic outbreak. Given these uncertainties, it is important to develop multiple mitigation strategies, involving vaccination, prophylaxis with antiviral drugs, and both voluntary and imposed changes in social patterns such as school closures and travel restrictions.
The course of an influenza outbreak is sensitive to many factors, particularly population mobility and the susceptibility of individuals to the virus. Traditional mathematical models of epidemics often take the form of deterministic SIR differential equations for the population dynamics of susceptible (S), infectious (I), and removed/recovered (R) individuals (5, 6). Such models have also been extended to model the geographic spread of infectious diseases (7, 8). However, the population-based nature of this class of models best describes the dynamics of an epidemic when large numbers of individuals are infected, rather than the initial or final stages of an outbreak, when small numbers of individuals are involved and stochastic person-to-person transmission processes dominate. To satisfactorily model the initial seeding and final quenching of small community-level outbreaks requires a fundamentally different approach. To capture this crucial effect of uncertainty in transmission on epidemic predictions, we develop and use a stochastic agent-based discrete-time simulation model. This class of model has been used to assess vaccination and antiviral prophylaxis strategies on a local level (911); larger-scale versions have recently been used to investigate strategies at a regional level for containing an emerging pandemic influenza strain at its source (3, 4). Our national-level model combines an individual-level description of influenza viral infection and transmission dynamics with high-fidelity U.S. Census Bureau and Department of Transportation data on population demographics and mobility, yielding a massive-scale simulation model of the spatiotemporal dynamics of spread of a pandemic strain of influenza virus among an artificial U.S. population of 281 million people. Such an endeavor is only now practical with modern parallel supercomputing platforms and programming techniques.

Results and Discussion
Top
Abstract
Results and Discussion
Conclusions
Materials and Methods
Acknowledgements
References

Simulation Model Design. The model population of 281 million individuals is distributed among 65,334 census tracts to closely represent the actual population distribution according to publicly available 2000 U.S. Census data (www.census.gov/main/www/cen2000.html). Each tract is in turn organized into 2,000-person communities. The model runs in cycles of two 12-hour periods ("day" and "night"), during which we identify seven contexts ("mixing groups") within which individuals can associate. In five of these contexts (households, household clusters, preschools, playgroups, schools, and work groups), relatively close person-to-person association regularly occurs. Additionally, "neighborhoods" and "communities" provide unspecified contexts (e.g., shopping malls) within which occasional casual person-to-person association occurs. Because each individual may interact with any member of his or her mixing group, the group sizes determine the numbers of people who would be considered for antiviral prophylaxis in our socially targeted strategy of mitigation (below). Daytime contacts occur in neighborhoods and communities as well as in the age-appropriate setting, and nighttime contacts occur only in households, household clusters, neighborhoods, and communities. U.S. Census data on tract-to-tract worker flow is used to model the commute of working adults to their workplace, thus accurately capturing the short- to medium-distance population mobility important for disease spread. In addition, each individual takes occasional long-distance trips (three per year on average), lasting between 1 day and 3 weeks (4.1 days on average), matching Bureau of Transportation Statistics data (www.bts.gov/publications/national_transportation_statistics). Our simple model of long-range travel could be extended to account for different types of travel (e.g., business or leisure) or groups of travelers (such as a family) or to explicitly incorporate the airline network structure, as in ref.8.
The disease transmission and natural history models are briefly described in Materials and Methods, with further details provided in Supporting Text, Figs. 3–5, and Tables 3–5, which are published as supporting information on the PNAS web site. To model the introduction of pandemic influenza into the U.S., we assume that impenetrable borders are either prohibitively expensive or impossible to create, and that international air travel is the dominant mode of influenza introduction from outside the U.S. Consequently, a small random number of incubating individuals, equivalent to 0.04% of arriving international passengers, is introduced each day at each of 14 major international airports in the continental U.S. (see Table 6, which is published as supporting information on the PNAS web site). The simulation covers 180 days, roughly the length of a U.S. influenza season. We assume that, because of the uncertainty in diagnosis of influenza infections and the sporadic nature of the early stages of an outbreak, a cumulative number of 10,000 symptomatic individuals nationwide is required to trigger a nationwide pandemic alert (see Supporting Text for a sensitivity analysis of various response delays, for selected intervention strategies).
Intervention Strategies. A variety of intervention strategies composed of one or more of the following four actions is considered: (i) socially targeted antiviral prophylaxis (TAP), in which symptomatic individuals and most of their close contacts receive treatment or prophylaxis, respectively, with antiviral drugs; (ii) dynamic mass vaccination, either of a random selection of individuals from the entire population or with preference for children, and with various production and distribution rates and starting dates; (iii) closure of schools, including preschools and play groups; and (iv) social distancing, as a result of legally mandated travel restriction or quarantine programs, or voluntary changes in social behavior.
TAP (11) is triggered by the first symptomatic person to be ascertained within a household (the index case). Because symptomatic diagnosis of influenza viral infection is inaccurate, leading either to delays in accurate diagnosis by biological assay or to excessive use of antivirals due to false positives, we simulate several scenarios. For the majority of our simulations, we assume that there are 0% false positives, and 60% of index cases are ascertained (the rest omitted because of, for example, misdiagnosis or lack of access to health care). When an index case is ascertained, he or she is treated, and all remaining people in this person’s household and household cluster are offered prophylaxis. If an ascertained index case belongs to a daycare, preschool, school, or workplace, then 100% of the people in that daycare or preschool are offered prophylaxis, or 60% of the people in that school or workplace. (Results for other ascertainment percentages, diagnosis delays, false positives, or prophylaxis strategies are presented in Supporting Text.) Due to its labor-intensive nature, TAP is likely to be feasible only during the earliest stages of an outbreak in any particular community, before the community health system is overwhelmed.
The dose and duration for effective treatment and prophylaxis using neuraminidase inhibitors (NAIs) against currently circulating strains of human influenza virus are well known (12), although a recent study suggests that an increased dose and duration of treatment may be needed to counteract H5N1 viral infections (13). On the other hand, these viruses may not retain their current unusually high growth rates if they evolve to be readily human-to-human transmissible. In light of this uncertainty, we use the current manufacturer’s recommended dose (10 tablets of oseltamivir for 5 days of treatment or 10 days of prophylaxis) and current estimates of oseltamivir efficacy in reducing infectiousness and susceptibility (see Supporting Text) (3, 14). Administration of a single course of NAI is initiated the day after the index case is ascertained, providing therapy for the index case and prophylaxis for others. A susceptible individual may receive subsequent courses of NAIs if another index case occurs later in a mixing group of which he or she is a member. We assume that 5% of people who start taking influenza antiviral agents will stop taking them after 1 day of treatment or prophylaxis.
Interventions involving vaccination suffer from uncertainty about the future identity of a pandemic strain, making it impossible to stockpile well matched pandemic vaccines. However, prevaccination based on a killed avian virus precursor to the pandemic strain is possible, providing a perhaps poorly matched but potentially efficacious vaccine. Vaccination can also be based on killed or live attenuated emergent pandemic virus, providing a close match to the subsequent circulating strains but available with a lag of a few months from emergence (in nonpandemic years, vaccine manufacture takes between 6 and 9 months). A "dynamic vaccination" scenario, in which vaccine becomes available incrementally, starting from as early as 2 months before, to as late as 2 months after, the first individual in the U.S. is infected, is investigated, with different production rates, total production amounts, and distribution policies (either uniformly throughout the population or preferentially to children). We compare the administration of the recommended two doses conferring best protection levels to a strategy in which twice as many people are given a single dose, assuming that a single dose of vaccine confers about half the protection of two doses (15).
Much uncertainty exists about the societal acceptability of options for creating social distance and thereby reduction in transmission. Given the importance of children in the transmission of influenza (16), school closure is likely to be an effective (albeit burdensome) social distancing policy. Although formally imposed quarantine or travel restriction policies are possible, voluntary changes in hygienic and social behavior (including travel plans) will undoubtedly occur. Indeed, the spontaneous public response to news of an approaching pandemic will affect social behavior in unpredictable ways, so the social distancing strategies explored here are hopefully realistic approximations to voluntary or imposed distancing at three different scales: at the levels of schools, local communities, and nationwide travel. At the local scale, this social distancing is assumed to manifest itself in a concentration of interactions within households and household clusters, and at longer scales we consider uniform reductions in the amount of long-range travel to as little as 1% of the normal frequency. (See Supporting Text for details of implementation.) Although the social distancing measures studied here form a necessary first step in modeling such effects on disease transmission, further investigation is needed into variations in contact structure that are not considered in our model (e.g., classroom size variations with geographic region and grade level, parents staying at home with sick children, and other venues and mechanisms for transmission).
Simulation Results. Independent realizations of our simulations for a given set of parameter values lead to very similar epidemic curves (see Supporting Text, Table 7, and, which are published as supporting information on the PNAS web site, for details including the estimation of R0). In the absence of intervention, for R0 = 1.9, our simulated pandemic begins with sporadic outbreaks occurring across the country in areas of dense population for 24 days before the outbreak is recognized (Table 1and Movie 1, which is published as supporting information on the PNAS web site). The pandemic peaks after 85 days, with a final illness attack rate of 43% (Table 2). The greatest nationwide activity is concentrated in a 2-month period when >100,000 people become ill each day, although local areas differ in the timing and duration of their highly active periods. This coincides quite well with waves of past pandemics; the 1957–1958 influenza A (H2N2) "Asian" virus initially appeared in June and July 1957, as sporadic cases in Iowa, Louisiana, and the West Coast, developing into local outbreaks during August 1957 before peaking in a 60-day period covering September and October 1957 (17). Similarly, the 1968–1969 influenza A (H3N2) "Hong Kong" virus first appeared as sporadic cases along the West Coast in July 1968, developing into local outbreaks 3 months later in October and peaking in December 1968 and January 1969, before finally ending in March 1969 (7).


View this table:
[in this window]
[in a new window]
Table 1. Characteristics of simulated pandemic influenza in the U.S. in the absence of interventions



View this table:
[in this window]
[in a new window]
Table 2. Simulated mean number of ill people (cumulative incidence per 100) and for TAP, the number of antiviral courses required for various interventions and R0

Although the dynamics of the pandemic in the absence of mitigation are clearly sensitive to R0, interestingly, this sensitivity is modest when R0 increases beyond 1.9 compared with the effect of increasing R0 from 1.6 to 1.9 (Table 1). We use as our guideline for adequate mitigation a reduction in the overall rate of illness to no greater than that of a typical influenza epidemic, 10%. The results presented in Fig. 2 and Table 2 suggest that as R0 increases from 1.6 to 1.9, a transition occurs from an outbreak that can be mitigated with moderate efforts, to one that can be mitigated only with vigorous application of multiple strategies. For example, several of the single interventions that we simulated are successful for R0 = 1.6, with TAP the most effective single intervention for our model of social mobility and transmission, provided adequate antiviral supplies exist and close contacts can be rapidly identified (see Fig. 1and Movie 2, which is published as supporting information on the PNAS web site). In contrast, for R0 = 1.7, 10.0 million courses are predicted to limit the national illness attack rate to 0.2%, but for R0 = 1.8, a prohibitively large 51 million courses would be required. Fewer courses do not control the pandemic, and an overall attack rate in excess of 10% ensues. An aggressive vaccine production and distribution plan may also be successful for R0 < 1.9 (see Movie 3, which is published as supporting information on the PNAS web site), particularly if initially targeted at children (18). With the exception of school closures for R0 =1.6, social distancing policies alone appear only to slow the pandemic without reducing its impact as measured by morbidity (see Movie 4, which is published as supporting information on the PNAS web site). Regardless of R0, unless drastic travel restrictions are imposed, the extent or duration of the pandemic is insensitive to details of the amount and location(s) of introductions of pandemic influenza virus in our simulations (see, which are published as supporting information on the PNAS web site). Due to the highly mobile U.S. population, the details of the introduction of the pandemic virus only affect the precise geographic spread and timing of the epidemic peak.



View larger version (102K):
[in this window]
[in a new window]
Fig. 1. Two simulated pandemic influenza outbreaks with R0 = 1.9, initiated by the daily entry of a small number of infected individuals through 14 major international airports in the continental U.S. (beginning on day 0). The tract-level prevalence of symptomatic cases at any point in time is indicated on a logarithmic color scale, from 0.03% (green) to 3% (red) of the population. No mitigation strategies are used in the baseline simulation (Left), resulting in a 43.5% attack rate. (Right) A 60% TAP intervention begins at day 31, or 7 days after the pandemic alert. At day 99, the nationwide supply of 20 million antiviral courses is exhausted, leading to a nationwide pandemic.



View larger version (42K):
[in this window]
[in a new window]
Fig. 2. Epidemic curves (note the logarithmic scale) demonstrating the effectiveness of several different mitigation strategies, as compared to the baseline scenario without any intervention, for different values of R0. See Table 2 for details of each intervention. In the case of vaccination, results shown here are for a uniform coverage of the entire population with a single-dose regimen.
For R0> 1.9, no single policy is predicted to be sufficient to mitigate an outbreak. For such highly transmissible strains, a combination of behavioral changes (to slow the spread) and therapeutic and prophylactic measures is essential. Throughout the range of R0 tested, antivirals, provided they are available in sufficient quantities and can be rapidly distributed, are a powerful tool for management. On the other hand, combinations of behavioral changes, together with a steady production of a low-efficacy vaccine throughout the pandemic (dynamic vaccination), can also successfully control pandemics of viruses with all except the highest level of transmissibility (Table 2 and Fig. 2). It is also important to note that the estimated benefits of preferentially vaccinating children are offset by the closing of schools, so that although one measure or the other is highly recommended, both together seem to offer no additional protection. Based on this result, the high societal cost of an extended closing of schools, requiring parents or grandparents to remain home with young children, may be avoidable through such a focused vaccination strategy. Similarly, our model suggests that the combination of TAP, school closure, and social distancing can be successful up to R0 = 2.4, without any vaccination (see Tables 8–10 and Figs. 10 and 11, which are published as supporting information on the PNAS web site, for additional combinations of intervention policies).
These projected major efforts necessary to mitigate pandemic influenza in the U.S. make it obvious that, for the U.S. and other countries, it would be optimal to control a potential pandemic strain of influenza at the source. In the event that a pandemic influenza virus does reach the U.S., according to our results, the U.S. population could begin to experience a nation-wide pandemic within 1 month of the earliest introductions. Our simulations indicate that the rapid imposition of a 90% reduction in domestic travel would slow the virus spread by only a few days to weeks (depending on R0), without reducing the eventual size of the outbreak, unless other behavioral or medical responses are introduced.

Conclusions
Top
Abstract
Results and Discussion
Conclusions
Materials and Methods
Acknowledgements
References

In this study, we regard strategies for mitigating pandemic influenza in the U.S. as successful when they limit the national attack rate to that of annual influenza epidemics, 10% of the U.S. population. All of our conclusions about the success of mitigation strategies are based on a simplified model of disease transmission and social contacts. Alternative models producing the same R0 may differ in quantitative details, but we expect the following conclusions to hold qualitatively. To achieve the target level of mitigation with antiviral agents alone, a very large stockpile is likely to be required (10 million courses of oseltimavir for R0 = 1.7, or 51 million courses for R0 = 1.8, in our simulations). For larger values of R0, the stockpile would have to be prohibitively large, e.g., 182 million courses for R0 = 1.9. Only for R0 1.6 is reasonable control predicted to be achievable with the small currently available stockpile of 5 million courses. Our articulated TAP strategy targets sites of transmission for prophylactic drug use (3, 11), consequently using much less drug than if geographic regions or large groups, such as entire schools, were targeted (3, 4). However, this TAP strategy requires the identification of the effective sizes of the close-contact mixing groups, which is much more difficult in practice than in our assumed contact structure model. Consequently, the implementation of TAP would require considerable up-front preparation or on-the-spot decision making, and its effectiveness may be reduced by unforeseen sites or mechanisms of transmission that are not included in our model. Nevertheless, we believe that, even when antiviral stockpiles are small, the TAP strategy could be quite effective in slowing virus spread until vaccination could be implemented. (Of course, the potential emergence of an antiviral-resistant strain should also be considered in any pandemic planning.)
When vaccine supplies are limited, our simulations indicate that, at a population level, vaccinating n people with the recommended two doses providing maximal protection is less effective at reducing attack rates than vaccinating 2n people with single doses, assuming that a single dose confers roughly half the protection of a two-dose regimen (which may or may not be an option, depending on the particular vaccine). The relative benefits of single-dose vaccination of 2n people and two-dose vaccination of n people are expected to hold for prevaccination using poorly matched avian virus seed stock, although benefits are expected to be less than those presented here. The most effective single mitigation strategy would be a rapid dynamic vaccination of the population, initiated within 2 weeks of the pandemic alert, with a single dose of vaccine from the pandemic virus. Specifically, for R0 1.6, spread could potentially be controlled if vaccine could be distributed nationally at the rate of 10 million doses per week for 25 weeks. For 1.9 R0 2.4, single-dose vaccination would likely require augmentation with some combination of TAP, social distancing measures, and travel restrictions to be effective. Assuming that children remain major spreaders during the early stages of a pandemic outbreak, as they are for interpandemic influenza (16), the preferential vaccination of school children should be much more effective than random vaccination unless schools are closed. If vaccination in advance of a pandemic were possible using an avian seed virus, use of this poorly matched vaccine could slow virus spread as much as possible until a well matched vaccine based on the emergent human pandemic virus could be deployed.
Based on the present work, with the assumptions inherent in our model and its parameters, we believe that a large stockpile of avian-based vaccine with potential pandemic influenza antigens, coupled with the capacity to rapidly make a better-matched vaccine based on human strains, would be the best strategy to mitigate pandemic influenza. This effort needs to be coupled with a rapid vaccine distribution system capable of distributing at least 10 million vaccine doses per week to affected regions of the U.S. For highly transmissible strains (i.e., having R0 1.9), social distancing policies, including school closure and/or travel restrictions, may also be required to slow the epidemic spread sufficiently to enable production and distribution of sufficient quantities of vaccine. If antivirals were the preferred therapeutic defense, a stockpile of 20 million courses could be sufficient to effectively reduce national spread of a virus with R0 up to 1.7, provided extensive planning and/or on-the-spot decision making to distribute antivirals in a timely fashion was carried out. If implemented for pandemic planning, such infrastructure for stockpiling and rapid deployment of therapeutics would lead to the more effective use of vaccines (18) and antiviral agents in annual influenza epidemics. On the other hand, travel restrictions alone do not appear to be an effective control strategy, due to the implausibly early and drastic measures required to significantly reduce the large number of local outbreaks that are likely to emerge around the country.
Although our simulation model was specifically designed for the U.S., we believe that the qualitative conclusions reached here will hold for other countries or regions with highly mobile populations. However, for quantitative predictions to hold in settings other than those explicitly studied here, it will be important to demonstrate a robustness to various assumptions inherent in the model and its parameters. (In the event of an actual pandemic, use of a model to make quantitative predictions will require a rapid characterization of the transmission dynamics, disease natural history, and vaccine and antiviral efficacies to estimate these key model parameters.) Then the computational tool introduced here, capturing both the stochastic transmission processes that dominate the initial stages and final extinction of an outbreak and the detailed spatiotemporal dynamics of infectious disease spread, can be applied to public health questions that cannot be effectively addressed with traditional mathematical models (5, 6). In particular, should avian influenza continue to spread throughout the world, it will be important to develop containment strategies, analogous to those proposed for Southeast Asia (3, 4), that anticipate the possibility of a human-to-human transmissible strain of H5N1 influenza emerging first in a highly mobile population such as Europe or the U.S.

Materials and Methods
Top
Abstract
Results and Discussion
Conclusions
Materials and Methods
Acknowledgements
References

Disease Transmission Model. Each class of mixing group is characterized by its own set of age-dependent probabilities of person-to-person contact of sufficient closeness and duration for transmission of normal human influenza virus to plausibly occur within a 12-hour period. Each of these contact probabilities is multiplied by the probability of transmission given contact, a single multiplicative constant that can be varied to model different R0 values. As described in Tables 3 and 4, the contact probabilities were calibrated against total and age-specific illness attack rates of data in past pandemics (3,9,17), although these attack rate data alone do not uniquely determine parameter estimates. Infection of susceptible individuals is modulated by the antiviral and vaccination statuses of both the infectious and susceptible persons. A susceptible individual has a daily probability of becoming infected, accumulated over his/her contacts within each of the mixing groups to which he/she belongs (see Supporting Text for details). Age-dependent distributions are used to determine individual disease progression, whether an infected person becomes ill or remains asymptomatic and, if symptomatic, when (if ever) the person withdraws to household-only contacts.
Disease Natural History Model. Predictions of the model are sensitive to the assumed disease course, but we can refer to past pandemics for guidance. The disease course for infection with the 1957 and 1968 pandemic influenza viruses and with post-1968 influenza A viruses (17) has been fairly consistent, with an estimated mean latent period of around 1.9 days and mean infectious period of around 4.1 days in several modeling studies (7, 9, 11, 20). The mean serial interval or generation time (i.e., average time between new infection and transmission to another susceptible) is thus 4 days. However, a recent reanalysis of incubation period and household transmission data suggests a significantly shorter serial interval of only 2.6 days, also consistent with viral shedding data from experimental infection studies (4). On the other hand, H5N1 virus is quite different from viruses causing past pandemics (including the 1918 pandemic), bearing the distinctive molecular signature of highly pathogenic avian influenza viruses, with possible implications for the resulting disease course in humans. The limited clinical information available to date on the disease course in individuals infected with H5N1 virus suggests a longer time course (13). Because H5N1 has not yet adapted for ready transmission among humans, and disease presentation may change in conjunction with this evolution, we focus on the midrange distributions in our model (see Fig. 3b), with a generation time of 3.5 days (3).
Model Limitations. No seasonal or environmental effects or viral evolution are modeled (although it would certainly be possible to do so); we assume constant contact, transmission, and disease course parameters throughout the U.S. for the entire duration of an influenza season. Disease-related mortality was also neglected, under the assumption that deaths would occur at the latter stages of the infectious period and thus not significantly affect the spread of disease. It is important to realize that, although we attempt to make realistic estimates of model parameters, model validation in the traditional sense is not possible due to the unpredictability of viral evolution and the impossibility of documenting all cases of influenza in any influenza season.




Acknowledgements
Top
Abstract
Results and Discussion
Conclusions
Materials and Methods
Acknowledgements
References

We are indebted to Norman Johnson, Peter Lomdahl, and Tim McPherson for several key contributions in the early stages of this work, and to Mike Brown, Neil Ferguson, Brad Holian, Ed MacKerrow, Jeff Newman, Gary Resnick, Tom Wehner, and Shufu Xu for their encouragement and suggestions. We also thank Tony Redondo, Andy White, and the Institutional Computing Program at Los Alamos National Laboratory for providing access to the necessary supercomputing resources. This work was supported by the Department of Homeland Security through program CBLA11MP (to T.C.G., K.K., and C.A.M.) and by National Institute of General Medical Sciences MIDAS Grant U01-GM070749 (to I.M.L.). Los Alamos National Laboratory is operated by the University of California for the U.S. Department of Energy under Contract W-7405-ENG-36.

Footnotes


Abbreviations: TAP, targeted antiviral prophylaxis; NAI, neuraminidase inhibitor.
To whom correspondence should be addressed. E-mail: tcg@lanl.gov
Author contributions: T.C.G., K.K., I.M.L., and C.A.M. designed research, performed research, contributed new reagents/analytic tools, analyzed data, and wrote the paper.
In fact, efficacy of experimental vaccines against a novel pandemic strain cannot be ascertained in the absence of actual viral challenge; immunogenicity alone can be determined. Experimental vaccines based on avian influenza virus have required much greater amounts of antigen for acceptable levels of immunogenicity than standard human vaccines. This discrepancy does not enter into our calculations of required doses of vaccine. We assume that pandemic vaccines will have the same relationship between efficacy and immunogenicity as that for standard vaccines against human influenza virus.
R0 is a difficult quantity to estimate during an actual epidemic, because it depends critically upon the disease serial interval (or generation time) and to a somewhat lesser extent on the relative durations of the latent and infectious periods (19, 20). Because our model assumes particular values for these quantities, R0 is a useful measure of transmissibility, but care needs to be taken when comparing results for different models or epidemiological data.
Conflict of interest statement: No conflicts declared.
© 2006 by The National Academy of Sciences of the USA

References
Top
Abstract
Results and Discussion
Conclusions
Materials and Methods
Acknowledgements
References
  1. Stöhr, K. & Esveld, M. (2004) Science 306, 2195–2196.[Abstract/Free Full Text]
  2. Tumpey, T. M., Basler, C. F., Aguilar, P. V., Zeng, H., Solórzano, A., Swayne, D. E., Cox, N. J., Katz, J. M., Taubenberger, J. K. & Palese, P., et al. (2005) Science 310, 77–80.[Abstract/Free Full Text]
  3. Longini, I. M., Nizam, A., Xu, S., Ungchusak, K., Hanshaoworakul, W., Cummings, D. A. T. & Halloran, M. E. (2005) Science 309, 1083–1087.[Abstract/Free Full Text]
  4. Ferguson, N. M., Cummings, D. A. T., Cauchemez, S., Fraser, C., Riley, S., Meeyai, A., Iamsirithaworn, S. & Burke, D. S. (2005) Nature 437, 209–214.[CrossRef][ISI][Medline]
  5. Kermack, W. O. & McKendrick, A. G. (1927) Proc. R. Soc. London Ser. A 115, pp. 700–721.
  6. Anderson, R. M. & May, R. M. (1991) Infectious Diseases of Humans (Oxford Univ. Press, Oxford, U.K.).
  7. Rvachev, L. A. & Longini, I. M. (1985) Math. Biosci 75, 3–22.[CrossRef][ISI]
  8. Hufnagel, L., Brockmann, D. & Geisel, T. (2004) Proc. Natl. Acad. Sci. USA 101, 15124–15129.[Abstract/Free Full Text]
  9. Elveback, L. R., Fox, J. P., Ackerman, E., Langworthy, A., Boyd, M. & Gatewood, L. (1976) Am. J. Epidemiol 103, 152–165.[Abstract/Free Full Text]
  10. Halloran, M. E., Longini, I. M., Nizam, A. & Yang, Y. (2002) Science 298, 1428–1432.[Abstract/Free Full Text]
  11. Longini, I. M., Halloran, M. E., Nizam, A. & Yang, Y. (2004) Am. J. Epidemiol 159, 623–633.[Abstract/Free Full Text]
  12. Moscona, A. (2005) N. Engl. J. Med 353, 1363–1373.[Free Full Text]
  13. Beigel, H., Farrar, H., Han, A. M., Hayden, F. G., Hyer, R., de Jong, M. D., Lochindarat, S., Tien, N. T. K., Hien, N. T. & Hien, T. T., et al. (2005) N. Engl. J. Med 353, 1374–1385.[Free Full Text]
  14. Yang, Y., Longini, I. M. & Halloran, M. E. (2006) Appl. Stat in press.
  15. Ritzwoller, D. P., Bridges, C. B., Shetterly, S., Yamasaki, K., Kolczak, M. & France, E. K. (2005) Pediatrics 116, 153–159.[Abstract/Free Full Text]
  16. Brownstein, J. S., Kleinman, K. P. & Mandl, K. D. (2005) Am. J. Epidemiol 162, 686–693.[Abstract/Free Full Text]
  17. Kilbourne, E. D. (1975) The Influenza Viruses and Influenza (Academic, New York).
  18. Longini, I. M. & Halloran, M. E. (2005) Am. J. Epidemiol 161, 303–306.[Abstract/Free Full Text]
  19. Fraser, C., Riley, S., Anderson, R. M. & Ferguson, N. M. (2004) Proc. Natl. Acad. Sci. USA 101, 6146–6151.[Abstract/Free Full Text]
  20. Mills, C. E., Robins, J. M. & Lipsitch, M. (2004) Nature 432, 904–906.[CrossRef][ISI][Medline]



__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #7  
Old April 16th, 2006, 06:48 PM
Laidback Al Laidback Al is offline
Editor, Senior Moderator
 
Join Date: Feb 2006
Posts: 5,639
Default Re: US readies flu pandemic response plan: report

Florida1, thanks for posting the text of this article. I wanted to look at the figures and tables, but all of the links lead back to the PNAS site for a logon.

Is there someway when you download the text file that you can capture the figures and tables? Thank you.
Reply With Quote
  #8  
Old April 16th, 2006, 06:54 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Re: US readies flu pandemic response plan: report

Sure...Funny how the links worked for me. LOL
It will take me awhile. Check back..LOL
__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #9  
Old April 16th, 2006, 07:14 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Table 1

Table 1. Characteristics of simulated pandemic influenza in the U.S. in the absence of interventions

Basic reproductive number, R01.61.92.12.4
Rate of spread: 1,000th ill person*14131211
10,000th ill person*29242219
100,000th ill person*48373429
1,000,000th ill person*70524639
Peak of epidemic*117857564
Daily number of new cases at peak activity2.3 M4.5 M6.0 M7.9 M
Number of days with >100,000 new cases86686052
Cumulative number of ill persons92 M122 M136 M151 M

M, million.
*Days after initial introduction.
__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #10  
Old April 16th, 2006, 07:15 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Table 2

Table 2. Simulated mean number of ill people (cumulative incidence per 100) and for TAP, the number of antiviral courses required for various interventions and R0


InterventionR0 = 1.6R0 = 1.9R0 = 2.1R0 = 2.4

Baseline (no intervention)32.643.548.553.7
Unlimited TAP (no. of courses)*0.06 (2.8 M)4.3 (182 M)12.2 (418 M)19.3 (530 M)
Dynamic vaccination (one-dose regimen)0.717.730.141.1
Dynamic child-first vaccination0.042.816.335.3
Dynamic vaccination (two-dose regimen)3.233.841.148.5
Dynamic child-first vaccination0.925.137.247.3
School closure1.029.337.946.4
Local social distancing25.139.244.650.3
Travel restrictions during entire simulation||32.844.048.954.1
Local social distancing and travel restictions||19.639.344.750.5
TAP,* school closure,** and social distancing**0.02 (0.6 M)0.07 (1.6 M)0.14 (3.3 M)2.8(20 M)
Dynamic vaccination, social distancing, travel restrictions,¶|| and school closure**0.040.20.64.5
TAP,* dynamic vaccination, social distancing, travel restrictions,¶|| and school closure**0.02 (0.3 M)0.03 (0.7 M)0.06 (1.4 M)0.1 (3.0 M)
Dynamic child-first vaccination,social distancing,s travel restrictions,|| and school closure**0.020.20.97.7

M, million.
*60% TAP, 7 days after pandemic alert, antiviral supply of 20 M courses unless stated.
10 million doses of a low-efficacy vaccine (single-dose regimen) per week.
Intervention continues for 25 weeks, beginning such that the first individuals treated develop an immune response on the date of the first U.S. introduction.
10 million doses of a high-efficacy vaccine (two-dose regimen) per week.
Intervention starting 7 days after pandemic alert.
||Reduction in long-distance travel, to 10% of normal frequency.
**Intervention starting 14 days after pandemic alert.
Exhausted the available supply of 20 M antiviral courses.




__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #11  
Old April 16th, 2006, 07:21 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Supporting Text

A. Simulation Model Details:
The three basic elements of our national-level simulation model are (i) a previously
developed stochastic agent-based model for disease spread at the community level; (ii)
detailed U.S. Census demographics and worker flow data for daily commuter traffic at
short distances and Bureau of Transportation Statistics data for less frequent long-range
travel behavior; and (iii) high-performance parallel computing expertise in modeling
millions to billions of particles on hundreds to thousands of processors. These three
components, each of which we describe below in some detail, are brought together to
provide a unique capability for a detailed modeling of disease spread in the
population.
1. Community-Level Stochastic Simulation Model
Population structure:
As the starting point for constructing our national simulation model, we use a discretetime
stochastic simulation model of disease spread within a structured 2,000-person
community. Similar models have been developed and applied previously to both
influenza (1-4) and smallpox (5). The model population is stochastically generated to
match census-based nationwide distributions of age, household size, and employment
status. Each person in the population belongs to one of five age groups: preschool-age
children (0-4 years), school-age children (5-18 years), young adults (19-29 years), adults
(30-64 years), and older adults (64+ years). Households consist of one to seven persons,
with either one or two adults, and are grouped randomly into clusters of four households
each, and further grouped into one of four nonoverlapping neighborhoods, each
containing 500 people. Every person also belongs to a set of close and casual contact
(also referred to as “mixing”) groups, ranging from their household and household cluster
(highest contact rates) to schools and workplaces, down to their neighborhood and the
entire community (with the lowest contact rates, representing occasional interactions in
malls, supermarkets, and churches, for instance).
All preschool-age children are assigned to either a neighborhood daycare center, with 14
children on average, or to one of several smaller neighborhood playgroups, each with
four children. Depending on their age, school-age children may belong to one of two
elementary school groups (each shared between two neighborhoods, with 79 students
each on average), to a community-wide middle school group (128 students on average),
or to a community-wide high school group (average 155 students). These school contact
groups are in general not actual schools but rather representative of the typical daily
interactions a student may have with classmates and other peers. According to
Census data, 93% of children 5–18 years old attend school, so we allow the remaining
7% to mix in the household, household cluster, neighborhood, and community during the
daytime. Working adults (restricted to those who are 19–64 years old) belong to a work
group of 20 people. Although in reality many work places are larger than 20 people, we
assume that workers make a contact of sufficient duration and/or closeness to transmit
influenza virus with a subset of the entire workforce at that location.
Disease transmission model
Transmission within each contact group is described by a contact probability ci (Table 3),
which may depend on the age of both the infectious and susceptible persons. This contact
probability represents the likelihood (within each 12-hour period) of having a contact of
sufficient duration and closeness for transmission of an infectious dose of influenza virus
to be possible between these two individuals in this social setting. The probability of
transmission given such contact, Ptrans, is a single scalar number that multiplies each
contact probability, allowing for a simple variation in contagiousness (typically
represented by the basic reproductive number, R0) without modifying the underlying
social interaction network parameters. We do not allow for any seasonal or weekly
variation in contact rates or transmission probability, and no births or nonflu-related
deaths are included in our model.
Each day, the probability of infection for each susceptible individual is computed based
on the transmission probabilities for each potential infectious contact, pi = Ptrans × ci. If
the infectious contact is receiving antiviral treatment, this transmission probability is
further multiplied by (1 – AVEi), where AVEi is the antiviral efficacy for infectiousness.
Similarly, if they have been vaccinated, the vaccine efficacy for infectiousness VEi
reduces the transmission probability by (1 – VEi). The transmission probability pi can be
further reduced for asymptomatic (yet infectious) contacts, as described in the next
section. The probability of a susceptible person becoming infected is then computed as a
product of all of the possible infectious contacts each day. Fig. 3 illustrates this
calculation for a susceptible adult (shown in blue), with one infectious child in the
household (HH), one infectious workgroup (WG) contact, and three other infectious
people in the wider community (Comm). The probability that this susceptible adult
becomes infected is
P = 1(1pHH
c a ) (1pWG
a a ) (1pComm
a a ) (1pComm
c a )2,
where c and a denote child and adult, respectively. (It is obviously trivial to generalize
this to the case where the two community children have different levels of infectiousness
due to therapeutic drugs or differing levels of severity, e.g., one symptomatic and the
other subclinical.) A Bernoulli trial is conducted by generating a uniform [0,1] random
number; if this number is less than P, the susceptible adult becomes infected and enters
the latent phase of infection. If desired, the source of infection can then be determined by
sampling from the relative contributions of each infectious contact to P (for instance, in
this example, an infection is most likely to be transmitted from the household child, but
all five infectious contacts have a finite probability of being identified as the source).
Disease natural history:
We use the same influenza natural history model as used previously (4), which for
completeness is recapitulated in Fig. 3. The main points are that the latent, incubation,
and contagious period durations are each sampled from discrete distributions, with mean
periods of 1.2, 1.9, and 4.1 days, respectively. (The contagious period includes both the
slight difference between latent and incubation periods, as well as the standard
postincubation period when symptoms appear in 67% of infected people.) Any
infectiousness that is not accompanied by overt symptoms (namely, the postlatent part of
the incubation period, if any, and the 33% of infected people who never develop
symptoms) is assumed to be half as great as the infectiousness of symptomatic
individuals, reducing the transmission probability pi by a factor of two.
As before (1-5), we also allow people who become ill to withdraw from all contact
groups except their household, with an age-dependent withdrawal probability and
distribution of the number of days of illness before withdrawal for influenza taken from
Elveback et al. (1).
Pandemic influenza model parameterization
The potential pandemic influenza strain was assumed to have an age-dependent attack
rate pattern between the historical 1957-1958 “Asian” influenza A (H2N2) (6) and 1968-
1969 “Hong Kong” influenza A (H3N2) (7) pandemic strains (see Table 4). For fitting
purposes, the attack rate pattern was calculated as an average of the final state of 500
independent communities that initially had 12 random infected people each (Fig. 4). As a
baseline, the contact rates in households, small play groups, and large day care centers
were taken from ref. 3, where an H2N2 strain was modeled. However, since this attack
rate pattern hits school-age children particularly hard (see Table 4), these rates had to be
reduced by about a factor of 3 (this is also evident in ref. 4, where a similar attack rate
pattern was fit to a model specific for Thailand). The rest of the contact contribution was
split between the remaining four contact groups (workgroups, household cluster,
neighborhood, and community). Fine tuning to generate the contact probabilities shown
in Table 3 was done by calculating the gradient vectors for the different age-dependent
attack rates with respect to the contact rate parameters, which gives a linear
approximation of the dependence of the attack rates as a function of the contact rates.
Although the fitting was merely done for isolated communities, we find that the national
model has a very similar attack rate pattern (see Table 4).
2. Data Sources
The fundamental geographic unit in our model is the census tract, which is defined as a
relatively stable geographic area with between 1,500 and 8,000 residents, with an
optimum size of 4,000 people. In the 2000 Census, there were 65,443 census tracts
containing 281,421,906 people in the U.S. (50 states and the District of Columbia),
corresponding to an average population of 4,300 per tract (see Fig. 5 for the actual
distribution of population sizes; www.census.gov/geo/www/tallies/tabgeo2k.html). We
round off the population of each tract to the nearest 2,000 persons and populate each tract
with the appropriate number of 2,000-person communities, each with households,
schools, and other mixing groups as described above. In addition, several urban tracts
have little or no residential population, but a large daytime worker population. We model
these by communities comprised solely of work groups (in addition to the broad but weak
community-level mixing), with an average of five 20-person work groups per each such
community (corresponding to the average number of work groups in the suburban
community model). In this way, we are able to realistically differentiate primarily
residential tracts (with few, if any, work groups) from primarily urban ones (including
some with few or even zero households). Each of the 180,492 model communities
making up the national model is stochastically generated in an independent manner, so
that no two communities within the nation are exactly identical.
Workplace tracts are chosen using the tract-to-tract worker flow data from the 2000
Census (CD-ROM special tabulation of Census 2000 data, available at
www.census.gov/mp/www/spectab/stp64-webpage.html), which also provides the total
number of working (and conversely, of unemployed) adults in each tract. The distribution
of home-to-work commuter distances (measured from one tract center to another and zero
if the home and work tracts are identical) is shown in Fig. 5. We note that these raw data
refers to where individuals were working during the Census 2000 reference week
(generally the last week of March 2000), which is why a significant number of people
(1.13 million, or 0.9% of the total workforce) were reported as working at locations 100
miles or more from their residence. We assume that such travel does not occur on a daily
basis and instead place these individuals in a workgroup in their home tract. A related
issue is the workers who were sick, on vacation, or otherwise absent from work during
the reference week, estimated at 2% of used persons. Because both vacations and sick
leave (withdrawal from workgroups) are included in the model, we compensate for these
uncounted workers by multiplying each tract-to-tract worker flow total by 1.02.
The third source of data in our model captures the infrequent and irregular long-distance
travel, such as business trips or vacations. We base this component on the 1995 American
Travel Survey data available from the U.S. Department of Transportation, Bureau of
Transportation Statistics*. The 1.00 billion person-trips (defined as 100 miles or longer
each way, within the U.S.) among the 263 million residents at that date leads to an
average of 3.8 trips per person, which we allocate according to the age group-specific
data in Table 5. The average trip duration according to these data are 4.3 nights; we
choose from a distribution between 0 and 11 nights according to the data in Table 5. For
the present implementation, each trip destination is a random neighborhood within a
random community (including workgroup-only communities), which results in a simple
“gravity” model with no distance information. The destination community determines
what types of contacts the traveler may have, in addition to the broad (but low-level)
neighborhood and community-level mixing groups. During the daytime, the traveler may
interact with his or her peers in play, school, or work groups if such contact groups exist
at the destination tract; and at nighttime, the traveler may interact with a household and
household cluster if traveling to one of the 78% of communities that are residential. In
future work, we plan to incorporate a more sophisticated model of long-distance travel,
which includes household and median destination income in determining trip frequencies,
travel purposes (which affect both the choice of destinations and the relevant contact
groups at the destination), and purpose- and distance-dependent distributions of trip
durations (J. P. Newman, T.C.G., K.K., and C.A.M., unpublished work). As an additional
step, the trips that are identified as air travel may be sampled from airline flight data,
capturing the long-distance travel component of disease transmission as realistically as
possible.
3. Computational Implementation
To implement this computationally demanding model, we use the high-performance
parallel molecular dynamics code “Scalable Parallel Short-range Molecular dynamics”
(SPaSM) (8), written in C with message passing interface (MPI) communication. In
recent years, this code has been used to model liquid- and solid-phase systems containing
millions to billions (9) of atoms, yielding insights into such varied physical processes as
dislocation dynamics (10), shock wave-induced plasticity (11), phase transformations
(12) in metals, and fluid instabilities (13). The present epidemiological model is readily
implemented in SPaSM (and presumably in similar particle-based codes) by replacing the
C data structure for atoms (consisting of properties such as particle type, position,
velocity, …) with one for persons (age, contact groups, immune system status, …),
interatomic force field interactions with a social network and disease transmission model,
and atomic classical mechanical trajectories with individual mobility rules (from
residence to workplace on a regular basis and occasional long-range travel). A typical
production run on 256 central processing units (CPUs) of a 2,048-processor Intel Xeon
2.4-GHz cluster with Myrinet interconnect took 8-12 h to complete a simulation of 180
days; depending on the disease parameters and amount of output, more CPU time was
necessary in some instances. In all, 200 production runs were performed, amounting to
70 CPU years of computer time.
B. Scenario
We assume that the pandemic influenza strain is introduced into the U.S. via arriving
international passengers. Furthermore, we assume that, by the time of this introduction,
there is an ongoing worldwide pandemic, so there is no particular country or region that
can be isolated (for instance, restricting arriving international flights from Southeast
Asia). Consequently, we consider the 14 largest international airport gateways (U.S.
Dept. of Transportation, U.S. International Air Passenger and Freight Statistics Report,
http://ostpxweb.dot.gov/aviation/usstatreport.htm) in the continental U.S. (see Table 6)
and introduce a small number of infected individuals each day. We do so by choosing a
random tract and community within each county listed in Table 6 and randomly infect
between 0 and N individuals (chosen randomly from a uniform distribution) in that
community. We take N proportional to the number of international arrivals at each
airport, assuming 1-10 potential infecteds per 10,000 daily passengers. This represents a
group of individuals, such as a family or business travelers, flying into the U.S. from the
assumed pandemic that is raging worldwide throughout the 180-day simulation. For most
simulations, we assume two infected persons per 10,000 daily international passengers,
but the sensitivity to this choice and to other issues related to the seeding of infecteds is
discussed below.
C. Basic Reproductive Number R0
The value of R0 was calculated for different transmission probabilities by three different
methods, yielding the results summarized in Table 7. The first method was to average the
number of secondary infections (omitting any tertiary infections) in 128,000 isolated
communities that each had one random index case within the 2,000-person community
population. (Using a smaller number of realizations, up to several thousand, led to
statistical errors too great to determine R0 within the desired ± 0.1 precision.) An example
of this calculated distribution and the resulting average R0 are shown for Ptrans = 0.12 in
Fig. 6, and these results are denoted “random index case” in Table 7.
The second method was similar, except that separate R0 first were calculated for index
cases belonging to each of the five age groups (see Table 7). The overall R0 was then
calculated as an average of these age group-dependent R0 values, weighted by the agedependent
attack rate pattern for the respective transmission probability (referred to as the
“attack rate pattern weighted index case” in Table 7). By doing this, the index case is
more “typical” of those hit hardest by the outbreak and, as expected, this method slightly
increases the value of R0 (particularly for low R0).
The last method is an approximation based on the slope of the cumulative number of
cases (14) and allows also for a time dependence of the reproductive number R(t) = 1 +
λν + f (1-f) (λν)2, where ν is the sum of the latent and infectious periods, which for our
model is 1.2 + 4.1 = 5.3 days, f is the relative duration of the latent period (i.e., 1.2
days/5.3 days for our model), and λ is the time derivative of the logarithm of the
cumulative number of cases N, i.e., λ = d[ln(N)]/dt. By seeding the 14 major international
hubs with eight initial infected per 10,000 daily international passengers only at day 0 of
the simulation, we calculated the basic reproductive number as a function of time (see
Fig. 7). Although there are large oscillations at early times due to the larger statistical
errors (from fewer cases), it is clearly noticeable that R is largest at early times and drops
later. This is related to the fact that school children are particularly important spreaders in
the initial stages of an influenza outbreak (see Fig. 7) due to their strong household and
school interactions, which then naturally enhances R (see Table 7). After 30 days, the
value for R stabilizes; in Table 7, we report (as “slope of cumulative number of cases”)
the average value between day 30 and the time when R begins to decline sharply, because
large parts of the nation are already affected. This approximation is in good agreement
with the value obtained by the second method, involving only single-community shorttime
simulations. We should note that the two former methods can give only an averaged
static value as an estimator, whereas the latter method can give information about the
time development of R. Here, early-time fluctuations and enhancement of the
reproductive number clearly demonstrate the difficulty in measuring this quantity from
available data in a real epidemic. Furthermore, this behavior is even more complicated by
the spatiotemporal spread of the epidemic, which causes local variations of R in time. It
should not be too surprising that the averaged static value of R0 for the community and
national models are similar, because, although the index case can interact with more than
one community in the latter simulation, the number of effective interactions is the same,
and in both cases, the populations are completely susceptible.
D. Intervention Strategies
1. Targeted antiviral prophylaxis (TAP)
Upon activation of a TAP program, symptomatic individuals and their close contacts are
treated with antiviral drugs, until a possibly limited national stockpile has been
exhausted. We assume that X% of symptomatic cases can be identified, and that 1 day
after the onset of illness, the sick individual is treated therapeutically and prophylaxis
offered to his/her close contacts. Of these, we assume that 100% of household, household
cluster, preshool, and playgroup contact are identified and treated, and that Y% of
workgroup and elementary, middle, and high school contacts are identified and treated.
For the present work, we will focus on two cases: X = Y = 60% or 80%, and refer to these
as “60% TAP” and “80% TAP,” respectively.
As in other recent models of pandemic influenza (4), we use reported estimates of the
antiviral efficacy for oseltamivir (15-19). Specifically, we assume that the antiviral
efficacy for susceptibility AVEs = 0.30, the antiviral efficacy for infectiousness AVEi =
0.62, and the antiviral efficacy for illness given infection AVEd = 0.60. For infected
individuals, antiviral treatment reduces the infectious period by 1 day (whether or not the
patient develops symptoms). Each course consists of 10 tablets, enough for 5 days of
therapeutic treatment or 10 days of prophylaxis. If a person who is taking prophylactic
course becomes ill, they complete their current course at the increased two tablets per day
dosage. We assume that full antiviral efficacy is attained with the first tablet, and that
there is no residual efficacy once the course has been completed.
2. Dynamic mass vaccination
Two major uncertainties in modeling any vaccination program are how effective the
vaccine will be (because, even for endemic influenza, it is typically matched against a
strain that is several months to 1 year old), and how quickly it can be produced,
distributed, and result in an effective immune response. As yet, the efficacy of
vaccination against a human-adapted avian strain is unknown. The immunogenicity of
experimental vaccines has been measured; it has been found that a 4-fold increase in
antigen content above that of vaccines against human strains, and two vaccine doses, are
required for a rise in antibody titer typically associated with protection (20). We assume
that efficacy and immunogenicity are linearly related in our simulations. The second
complication is related to timing. The time lag between vaccination and full effectiveness
depends on the particular vaccine; for instance, a live attenuated vaccine may produce an
antibody response within 1 day, whereas a killed vaccine may take 2 weeks. If multiple
doses are required, the timescale can be significantly longer; for instance, two doses of a
killed vaccine administered 4 weeks apart means that full efficacy may not be attained
until 6 weeks after the initial dose. Rather than dealing with the specifics of any particular
vaccine (including partial efficacy between the administration of the first and second
doses), we simply combine this delay time with that for production and distribution and
refer only to the date at which vaccination becomes effective, which may be either before
or after the outbreak begins.
We consider two alternative distribution strategies, either randomly throughout the entire
eligible population or preferentially to children (with any remaining vaccine then
distributed among adults). In either case, the eligible population consists of all individuals
who have not been vaccinated and are not currently symptomatic. For simplicity, we
consider only two alternative production scenarios, either assuming the early distribution
of a low-efficacy (e.g., a poorly matched) vaccine or the delayed production of a higherefficacy
vaccine. The well matched vaccine is assumed to require two doses and to have a
vaccine efficacy for susceptibility VEs = 0.70 (with a reduced VEs = 0.50 for the elderly,
age 65+), and a vaccine efficacy for infectiousness VEi = 0.80. The poorly matched
vaccine has only VEs = 0.30 (for all age groups) and VEi = 0.50 and is assumed to require
only a single dose [which would not be the case for an avian influenza A (H5N1) virusbased
vaccine, for instance (20)]. It is assumed that early production of the poorly
matched vaccine allows for a vaccination program before the outbreak, resulting in a
prior coverage of some fraction of the population (again, either uniformly or
preferentially to children). For either vaccine, we assume a constant production and
distribution rate of 4, 10, or 20 million doses per week nationwide, starting as soon as 2
months before the first introduction, to as late as 2 months after the first introduction. The
total production is also assumed to be limited to 50, 100, 250, or 400 million doses.
3. School closure
Upon recognition of a pandemic strain in the U.S., one of the likely mitigation strategies
is the closure of schools [U. S. Department of Health and Human Services (HHS)
Pandemic Influenza Response and Preparedness Plan, www.hhs.gov/pandemicflu/plan].
We assume this involves a total nationwide closure all of the school-related mixing
groups in our model, and that this closure remains in effect for the duration of the
pandemic. The affected mixing groups are the regular preschool-age playgroups,
preschools, and elementary, middle, and high schools. All other contact rates remain
unchanged.
4. Social distancing
As a result of either a formal quarantine program or voluntary changes in social and
hygienic behavior in the event of a widespread pandemic, it is likely that normal contact
behavior will be affected in times of crisis. Although this alteration is difficult to predict
in advance, it almost surely will involve an increased tendency to remain at home rather
than in large public places. To approximate this behavioral modification, we assume that
the contact rates are cut in half for the community, neighborhood, work group, school,
preschool, and playgroup mixing groups; household contact rates are doubled; and
household cluster contact rates remain unchanged. As with the other mitigation strategies,
it is assumed that this alteration in normal behavior occurs nationwide and lasts
throughout the remainder of the epidemic.
5. Reductions in travel
We consider reductions in both of our travel components: the daily workplace travel and
irregular long-range travel. The first may be curtailed by voluntary increases in
telecommuting or, in extreme cases, by a nationwide work stoppage (with the exception
of health care and emergency personnel, as described below). Reductions in long-range
travel may also range from a component of the natural social distancing tendency to an
imposed quarantine or travel restriction program. We assume that long-range travel may
be reduced to as little as 1% of the normal number of trips.
E. Sensitivity Analyses
In this section, we explore sensitivity to various components of the model, including how
the epidemic is introduced, delays in implementing intervention strategies, and the
assumed effectiveness (or public compliance) with each intervention. Although each of
these variations naturally leads to quantitative changes in the precise quantitative results,
the basic conclusions presented in the main text are all relatively insensitive to any of the
variations that we have explored.
1. Stochastic variability
Because the model is inherently stochastic (including mock population generation,
introduction of new infecteds, daily disease transmission, and intervention strategy
components), in theory, we need to run several realizations for each scenario, each with a
different initial random seed. (For parallel runs, each processor uses a different seed to
avoid having exactly identical communities anywhere in the simulation.) However, we
have observed that between the large degree of spatial averaging over the 180,000
communities making up the national model and the daily introduction of new infecteds,
which demands a robust intervention strategy, there is almost no variation in either the
nationwide epidemic curve or final attack rate but only subtle differences in the specific
timing and geographic details of the epidemic spread. For instance, we compared eight
different baseline (no intervention) realizations for R0 = 1.6, differing only by the initial
random number generator seeds. All eight simulations give nearly identical final attack
rates (four simulations give 32.62%, three give 32.63%, and one gives 32.64%), with the
epidemic peaking between 115 and 120 days after the first U.S.introduction in all
realizations.
2. Seeding of the epidemic
To investigate sensitivity against different introductions of infected individuals (size and
spatial distribution of these individuals, as well as dynamic vs. static seeding), different
amounts of travel, as well as different random seeds (i.e., stochastic behavior), a series of
runs with no intervention is presented for R0 = 1.9 (similar results were obtained for other
choices of R0). Fig. 8 shows the sensitivity to the dynamic seeding rate, from one to four
infected persons per 10,000 international passengers each day at the major 14 U.S.
international air hubs, as well as a static seeding of eight infecteds per 10,000
international passengers only at the beginning of the simulation (corresponding to 76
infected people introduced on day 0). It can be clearly seen that the size of the seed and
the effect of static vs. dynamic seeding only shifts the epidemic curves without affecting
the shape or overall attack rate (43.53% in all cases).
The static seeding on day 0 is further explored in Fig. 8, comparing the dispersed
introduction of 76 infected people at 14 airports with 40 infected people all localized
either in Los Angeles County or New York County. Once again, the different seeding
changes only the timescale of the pandemic outbreak but not the shape or magnitude of
the epidemic curve. Although nationally averaged measures such as this (or others,
including the number of antiviral courses required for a TAP intervention) do not depend
on the size or distribution of the seeding, the precise details of the spatiotemporal
evolution do. This is illustrated for the Los Angeles and New York County seeds in Fig.
9, showing that very different geographic spreads can yield virtually identical national
epidemic curves (Fig. 8).
Fig. 8 also shows the effect of drastic reductions in long-range travel, to only 1-10% of
the normal levels during the entire 180 days of the simulation, for an initial introduction
in Los Angeles County. Here it can be seen that the width of the epidemic curve widens
and the peak shifts to later times, both useful factors when considering the demand upon
the health care system and resource allocation. Even though these reductions reflect
nearly a complete halt of nonessential travel (other than local commuter travel to
workplaces), with only 1–10% of leakage or essential emergency travel, the total attack
rate after 180 days is unchanged. Also shown in Fig. 8 is the epidemic curve for a
simulation for which a travel reduction to 1% of normal levels is imposed only after the
pandemic alert threshold, which is reached on day 38 in this case. Here one can see that
the (already marginal) effectiveness of travel restrictions is reduced even further if the
virus is given any time to spread, because it may introduce many small pockets of
infection that are able to develop despite the draconian measures.
3. Vaccine production, distribution, and effectiveness delays
Because an intervention strategy of vaccination alone is unlikely to ever succeed for R0 >
1.9 (see Table 2), we show in Table 8 the effectiveness of different production rates,
limits, and starting dates for R0 = 1.6. In addition to the necessity for both high
production rates and limits (which are more important than the exact starting dates), we
find a clear advantage to a preferential vaccination of children, as has been suggested
recently (21). Perhaps more surprisingly, we find that a more widespread vaccination
coverage with a lower efficacy is decidedly more effective than a higher-efficacy
vaccination of half as many people (also shown in Fig. 10), even before taking into
account the additional 4-6 weeks, which may be required to elicit a strong immune
response from a two-course vaccine program.
4. Targeted antiviral prophylaxis: Delays in policy implementation and patient
diagnosis
There are two timescales that may affect the effectiveness of a TAP program. The first of
these is at the population-wide public health scale, involving the time required to
recognize that a nascent pandemic outbreak is underway and implement a public health
response. The second timescale is at the individual level, involving the time it takes from
the first appearance of symptoms, before the person visits their doctor or urgent care
center, to a correct diagnosis and prescription of antiviral treatment for the patient, to
prescription and delivery of prophylactic courses to that patient’s close contacts. In Fig.
10, we show (for R0 = 1.9) the increasing number of antiviral courses required and the
increasing attack rate, the longer it takes to initiate a TAP program. (Day 0 on this axis
refers to a policy that is in place even before the first introduction of a pandemic
influenza strain into the U.S.) Clearly, an early intervention has benefits by reducing both
the incidence rate and the demand on the limited antiviral supply.
In the event (or even the threat) of a nascent pandemic, a major challenge will be to
correctly distinguish patients with the pandemic influenza strain from the larger number
of individuals with general respiratory symptoms (possibly, but not limited to, those
caused by a conventional strain of influenza). In a typical flu season, only 10-30% of
patients presenting flu-like symptoms actually test positively for influenza; were antiviral
treatment and prophylaxis of close contacts to be offered based on symptoms alone, a
limited stockpile could be rapidly exhausted. The TAP interventions modeled here
assume the availability of a large number of rapid test kits and testing locations (e.g.,
workplaces and convention centers, in addition to health care offices). With such a
capability, positive identification and antiviral distribution could be achieved within 1
day of the first appearance of symptoms. To examine the sensitivity to this assumption,
we have also carried out a few simulations with a 2-day lag between the appearance of
symptoms and the antiviral treatment and close-contact prophylaxis, as shown in Table 8
for an 80% TAP intervention.
Finally, Table 9 compares the 60% and 80% TAP programs, indicating the need for both
early intervention (as seen in Fig. 10) and for a high identification rate. For instance, a
nascent pandemic outbreak with R0 = 1.9 can be contained with only 27 million courses if
an 80% TAP strategy is implemented as late as 7 days after the pandemic alert threshold
(starting 3 days earlier, at 4 days after the alert, requires only 20 million courses), which
is within the planned national antiviral stockpile. However, a 60% TAP program initiated
at the same time is moderately successful but consumes 182 million courses, currently a
prohibitively large supply of antivirals. We also find that it is important to be able to
ascertain close contacts beyond the household, including school and work group peers
and household clusters; 60% TAP with only prophylaxis of the household uses few
courses but with a significantly higher total attack rate.
5. Social distancing strategies, including travel restrictions
As discussed in the main text, all of the social distancing strategies we have examined
serve only to slow down the epidemic spread but are ineffective at reducing the overall
attack rate (shown in Table 9 for a combination of all social distancing measures). The
example of long-distance travel restrictions is discussed in Sensitivity Analyses 2 for the
static one-time introduction of infecteds into Los Angeles (Fig. 8) and is illustrated in
Fig. 11 and Table 9 for the usual daily introduction through airport hubs, for R0 = 1.9 and
2.4. Although the final national attack rates are virtually unaffected, drastic reductions in
long-range travel to 1–10% of the normal rates clearly spreads out the pandemic into two
waves: after an initial peak in the sites of introduction (which occurs at the same time as
the baseline case without any intervention), a secondary peak as long as 2 months later
corresponds to the nationwide spread. In addition to buying time for vaccine production
and other mitigation strategies to be used, the distinct spatial evolution may aid the health
care response, because resources can gradually be shifted from the sites of initial
introduction to the secondary sites in the rest of the country.
6. Combined mitigation strategies
Table 10 shows results for several combinations of the mitigation strategies, both
therapeutic (vaccines and/or antivirals) and social distancing (including school closure
and travel restrictions). The key ingredients of any response plan seem to include both
TAP and school closure if a pandemic with potential R0 as high as 2.4 is to be avoided,
although one of these measures (but not both) may be omitted if R0 < 2.1.
F. Simulation Movies
All movies are single realizations for R0 = 1.9, with the standard daily introduction of
infected people through 14 major international airports, as described above. As in Fig. 1
of the main text, each census tract is shown as a dot colored according to the current
prevalence, on a logarithmic scale from green for 0.03% or fewer ill people per capita, to
red for 3% or greater. The corresponding epidemic curves (averaged over the entire
nation) are also shown.
*Available at www.bts.gov/publications/national_transportation_statistics. More recent
(2001) data define long-distance as trips 50 miles or greater of which nearly half (47.7%)
are <200 miles roundtrip and only 7.4% are via airplane (of 9.2 such trips per person each
year). Although the 1995 definition of long-distance travel as 100 miles or greater is still
dominated by automobile travel (81.3%), the mean roundtrip distance of 826 miles is
much more suitable for the distance-independent gravity model used here.
†This leads to a minor inconsistency, in that the eligible population is determined at the
date at which full effectiveness is reached and not at the earlier date of vaccination.
However, this study is concerned with strategies to minimize the number of infected
individuals, in which case the number of new symptomatic cases (who become ineligible
for vaccination) between these two dates is negligible.
1. Elveback, L. R., Fox, J. P., Ackerman, E., Langworthy, A., Boyd, M. & Gatewood, L.
(1976) Am. J. Epidemiol. 103, 152-165.
2. Halloran, M. E., Longini, I. M., Cowart, D. M. & Nizam, A. (2002) Vaccine 20, 3254-
3262.
3. Longini, I. M., Halloran, M. E., Nizam, A. & Yang, Y. (2004) Am. J. Epidemiol. 159,
623-633.
4. Longini, I. M., Nizam, A., Xu, S., Ungchusak, K., Hanshaoworakul, W., Cummings,
D. A. T. & Halloran, M. E. (2005) Science 309, 1083-1087.
5. Halloran, M. E., Longini, I. M., Nizam, A. & Yang, Y. (2002) Science 298, 1428-1432.
6. Kilbourne, E. D. (1975) The Influenza Viruses and Influenza (Academic, New York).
7. Rvachev, L. A. & Longini, I. M. (1985) Math. Biosci. 75, 3.
8. Beazley, D. M.& Lomdahl, P. S. (1994) Parallel Comput. 20, 173.
9. Kadau, K., Germann, T. C. & Lomdahl, P. S. (2004) Int. J. Modern Phys. C 15, 193.
10. Zhou, S. J., Preston, D. L., Lomdahl, P. S.& Beazley, D. M. (1998) Science 279,
1525-1527.
11. Holian, B. L. & Lomdahl, P. S. (1998) Science 280, 2085-2088.
12. Kadau, K., Germann, T. C., Lomdahl, P. S. & Holian, B. L. (2002) Science 296,
1681-1684.
13. Kadau, K., Germann, T. C., Hadjiconstantinou, N. G., Lomdahl, P. S., Dimonte, G.,
Holian, B. L. & Alder, B. J. (2004) Proc. Natl. Acad. Sci. USA 101, 5851-5855.
14. Lipsitch, M., Cohen, T., Cooper, B., Robins, J. M., Ma, S., James, L., Gopalakrishna,
G., Chew, S. K., Tan, C. C., Samore, M. H., et al. (2003) Science 300, 1966-1970.
15. Hayden, F. G. & Aoki, F. Y. (1999) in Antimicrobial Therapy and Vaccines, eds. Yu,
V., Meigan, T. & Barriere, S. (Williams & Wilkins, Baltimore), pp. 1344-1365.
16. Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond,
J. M., Sharp, S. J. & Ossi, M. J. (2000) N. Engl. J. Med. 343, 1282-1289.
17. Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, J. M., Elliott, M. J. & Crisp,
A. (1999) J. Am. Med. Assoc. 282, 31.
18. Welliver, R., Monto, A. S., Carewicz, O., Schatteman, E., Hassman, M., Hedrick, J.,
Jackson, H. C., Huson, L., Ward, P. & Oxford, J. S. (2001) J. Am. Med. Assoc. 285, 748.
19. Yang, Y., Longini, I. M. & Halloran, M. E. (2006) Appl. Stat., in press.
20. Altman, L. C. (August 7, 2005) N.Y. Times, p. 1.
21. Longini, I. M. & Halloran, M. E. (2005) Am. J. Epidemiol. 161, 303.
__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #12  
Old April 16th, 2006, 08:20 PM
hawkeye hawkeye is offline
Administrator, Editor
 
Join Date: Feb 2006
Posts: 4,840
Default Figure 3

Florida1 asked me to post this chart, I don't have a website to host the image so I've attached it as a file.

-hawkeye
Attachment 135
Attached Images
File Type: gif chart.gif (16.0 KB, 100 views)
Reply With Quote
  #13  
Old April 16th, 2006, 08:25 PM
sharon sanders's Avatar
sharon sanders sharon sanders is offline
Editor-in-Chief & President
 
Join Date: Feb 2006
Posts: 23,673
Default Description of Figure 3 above

Fig. 3. (a) Example of the calculation of the daily probability that a susceptible individual (blue) will become infected, due to infectious people (red) in various contact groups. For clarity, only the four household members and infectious contacts are shown; in general, each person may potentially come into contact with as many as 4,000 persons each day (2,000 each at their daytime and nighttime community locations). (b) Modeled natural history of influenza. Newly infected people pass through an incubation stage lasting from 1 to 3 days, slightly longer than the latent period during which they are completely noninfectious. Following the incubation period, we assume that 67% of infected people develop clinical symptoms, while 33% are asymptomatic and only half as infectious (the same as during the last day of the incubation period). Antiviral treatment is assumed to reduce both the likelihood of developing symptoms if infected and the infectious period by 1 day. Antivirals and vaccines can both reduce the infectiousness and susceptibility of infected and uninfected people, respectively.
__________________
"May the long time sun
Shine upon you,
All love surround you,
And the pure light within you
Guide your way on."

"Where your talents and the needs of the world cross, lies your calling."
Aristotle

“In a gentle way, you can shake the world.”
Mohandas Gandhi

Be the light that is within.
Reply With Quote
  #14  
Old April 16th, 2006, 09:37 PM
Laidback Al Laidback Al is offline
Editor, Senior Moderator
 
Join Date: Feb 2006
Posts: 5,639
Default Re: US readies flu pandemic response plan: report

Quote:
Originally Posted by Florida1
Sure...Funny how the links worked for me. LOL
It will take me awhile. Check back..LOL

Thanks a lot.
Reply With Quote
  #15  
Old April 16th, 2006, 09:51 PM
DB DB is offline
Valued Member
 
Join Date: Feb 2006
Posts: 1,404
Default Re: US readies flu pandemic response plan: report

Images from Plan:

Attachment 151

Attachment 137

Attachment 138

Attachment 139

Attachment 140
Attached Images
File Type: gif 2.gif (39.4 KB, 108 views)
File Type: gif 3.gif (73.6 KB, 97 views)
File Type: gif 4.gif (26.5 KB, 88 views)
File Type: gif 5.gif (67.0 KB, 86 views)
File Type: gif 6.gif (60.6 KB, 102 views)
File Type: gif Image2b.gif (19.6 KB, 87 views)
Reply With Quote
  #16  
Old April 16th, 2006, 09:53 PM
DB DB is offline
Valued Member
 
Join Date: Feb 2006
Posts: 1,404
Default Re: US readies flu pandemic response plan: report

Images from plan
Attachment 141

Attachment 142

Attachment 143

Attachment 144

Attachment 145
Attached Images
File Type: gif 7.gif (373.5 KB, 87 views)
File Type: gif 8.gif (41.9 KB, 87 views)
File Type: gif 9.gif (29.4 KB, 82 views)
File Type: gif 10.gif (25.0 KB, 99 views)
File Type: gif 11.gif (24.3 KB, 88 views)
Reply With Quote
  #17  
Old April 16th, 2006, 09:55 PM
DB DB is offline
Valued Member
 
Join Date: Feb 2006
Posts: 1,404
Default Re: US readies flu pandemic response plan: report

Images from plan
Attachment 146

Attachment 147

Attachment 148

Attachment 149

Attachment 150
Attached Images
File Type: gif 12.gif (11.4 KB, 83 views)
File Type: gif 13.gif (25.5 KB, 92 views)
File Type: gif 14.gif (17.9 KB, 84 views)
File Type: gif 15.gif (29.5 KB, 88 views)
File Type: gif 16.gif (27.0 KB, 97 views)
Reply With Quote
Reply


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On


Disclaimers:

The reader is responsible for discerning the validity, factuality or implications of information posted here, be it fictional or based on real events. Moderators on this forum make every effort to review the material posted on this site however, it is not realistically possible for our staff to manually review each post.

The content of posts on this site, including but not limited to links to other web sites, are the expressed opinion of the original authors or posters and are not endorsed by, or representative of the opinions of, the owners or administration of this website. The posts on this website are the opinion of the specific author or poster and should not be construed as statements of advice or factual information.

Not all posts on this website are intended as truthful or factual assertion by their authors. NO posts on this website should be considered factual information on face value alone. Users are encouraged to USE DISCERNMENT and do their own follow up research while reading and posting on this website. FluTrackers.com Inc. reserves the right to make changes to, corrections and/or remove entirely at any time posts made on this website without notice. In addition, FluTrackers.com Inc. disclaims any and all liability for damages incurred directly or indirectly as a result of a post on this website.

This site is provided "as is" without warranty of any kind, either expressed or implied. You should not assume that this site is error-free or that it will be suitable for the particular purpose which you have in mind when using it. In no event shall FluTrackers.com Inc. be liable for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with the use or performance of this site or other documents which are referenced by or linked to this site.

Finally, FluTrackers.com Inc. reserves the right to delete, correct, or make changes to any post on this website without notice at any time for any reason.

Fair Use Notice:
This site may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. Users may make such material available in an effort to advance awareness and understanding of issues relating to public health, civil rights, economics, individual rights, international affairs, liberty, science & technology, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C.Section 107, the material on this site is distributed to those who have expressed a prior interest in receiving the included information for research and educational purposes.

In accordance with industry accepted best practices we ask that users limit their copy / paste of copyrighted material to the relevant portions of the article you wish to discuss and no more than 1 paragraph, and in no case more than 50% of the source material provide a link back to the original article and provide your original comments / criticism in your post with the article. Please remember you are responsible for what you post on the internet and you could be sued by the original copyright holder if you do not honor these rules.

If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of "Fair Use" and legitimately infringes on yours or your clients copyright

we may be contacted concerning copyright matters at:

FluTrackers.com Inc.
c/o Sharon Sanders
1676 Hibiscus Avenue
Winter Park, Florida 32789
Phone: 407-745-1513
E-Mail: flutrackers@earthlink.net

In accordance with section 512 of the U.S. Copyright Act our contact information has been registered with the United States Copyright Office. "Safe Harbor" noticing procedures as outlined in the DMCA apply to this website concerning all 3rd party posts published herein.

If notice is given of an alleged copyright violation we will act expeditiously to remove or disable access to the material(s) in question.

All 3rd party material posted on this website is the copyright of the respective owners / authors. FluTrackers.com Inc. makes no claim of copyright on such material.

For more information please visit: http://www.law.cornell.edu/uscode/17/107.shtml

Please be aware any communications sent complaining about a post on this website may be posted publicly at the discretion of the administration.

FluTrackers Does Not Provide Any Medical Advice:

FluTrackers, Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster.

The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website.

By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.

By using and/or accessing this site, either passively or actively, you are agreeing to all of the above conditions. Also, by using and/or accessing this site, either passively or actively, you agree to conduct all business and legal affairs related to this website in the jurisdiction of Flutrackers.com Inc. which is registered in Central Florida, USA.

These Disclaimers are subject to change at anytime.

Email the Webmaster with questions or comments about this site at flutrackers@earthlink.net


All times are GMT -5. The time now is 05:39 AM.


H1N1 Influenza Swine Flu Avian Flu Infectious Diseases. Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2013, Jelsoft Enterprises Ltd.
Template-Modifications by TMS